An article highlighting Pairnomix’s efforts to “bridge the gap” between genetic diagnosis and treatment for patients with rare disease was published in the Winter 2018 edition of the European Biopharmaceutical Review.
Written by Gregory Stewart, PhD, Chief Scientific Officer at Pairnomix, the article calls attention to the increased utilization of genetic sequencing as a diagnostic tool and to the absence of treatment information for an identified genetic mutation. The article also describes how the approach used by Pairnomix can bridge this therapy gap.
Credit: This article is taken from European Biopharmaceutical Review January 2018, pages 52-57. © Samedan Ltd. For a link to the current edition of the European Biopharmaceutical Review, please click here.